ProKidney Corp. Asset Resilience Ratio
ProKidney Corp. asset resilience ratio. ProKidney Corp. (PROK) has an Asset Resilience Ratio of 42.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ProKidney Corp. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ProKidney Corp. (2022–2025)
Asset resilience ratio of ProKidney Corp. from 2022 to 2025. This chart shows how ProKidney Corp.'s Asset Resilience Ratio has changed over time. Read PROK current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ProKidney Corp.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of ProKidney Corp..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $106.70 Million | 42.85% |
| Total Liquid Assets | $106.70 Million | 42.85% |
Asset Resilience Insights
- Very High Liquidity: ProKidney Corp. maintains exceptional liquid asset reserves at 42.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ProKidney Corp. Industry Peers by Asset Resilience Ratio
Compare ProKidney Corp.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
ProKidney Corp. Asset Resilience Ratio by Year (2022–2025)
ProKidney Corp. asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for ProKidney Corp..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.12% | $161.48 Million | $335.57 Million | -10.64pp |
| 2024-12-31 | 58.76% | $259.17 Million | $441.07 Million | -13.12pp |
| 2023-12-31 | 71.88% | $302.30 Million | $420.55 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $518.00 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more